Biotechnology - Specialty Pharmaceuticals (Acute Care & Oncology)
Strategic Profile
The company reported $154.9 million net revenue for 2025, driven by a 65.1% year-over-year rise in its Acute Care franchise. The company issued 2026 guidance of $173–$183 million net revenue and $10–$20 million adjusted EBITDA. Heron has built a robust intellectual property portfolio around its biochronomer technology and product formulations, providing a strategic barrier against competition.
Cyborg Score Rationale
Heron is entering 2026 with exceptional momentum, with Acute Care net revenue climbing 65% in 2025 to $49.6M and a 2026 outlook of $173–$183M revenue. Strong commercial execution and product adoption offset some operational complexity, though the company faces competitive pressures and regulatory dependencies.
Top Insights
Acute Care franchise delivered 65% revenue growth in 2025 led by ZYNRELEF and APONVIE product adoption
Secured permanent product-specific CMS J-Codes (J0668 for ZYNRELEF, J8502 for APONVIE) improving billing clarity and reimbursement
APONVIE received inclusion in Fifth Consensus Guidelines for postoperative nausea and vomiting management
Completed debt restructuring reducing total debt from $175M to $145M with maturities extended to at least 2030
Named Competitors
EXPAREL — Leader in non-opioid pain management solutions
BARHEMSYS — PONV prevention alternative
Oncology franchise — Global pharmaceutical company with strong oncology presence
Cancer therapies — Biotechnology company for serious illnesses
Recent Developments
(February 2026) Full-year 2025 revenue of $154.9M with 2026 guidance of $173-$183M
(December 2025) Won patent court case against Fresenius Kabi securing CINVANTI patents through 2035
(December 2025) Relocated headquarters from San Diego to Cary, North Carolina
(December 2025) APONVIE included in Fifth Consensus Guidelines for PONV management
Open the full interactive Heron Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.